Cargando…

Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report

BACKGROUND: Immune checkpoint blockade targeting programmed cell death ligand-1 (PD-L1)/programmed death-1 (PD-1) signaling was approved recently for locally advanced and metastatic urothelial bladder carcinoma (UBC). Some patients experience a very rapid tumor progression, rather than clinical bene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Shiyu, Zhang, Junfeng, Guo, Yadong, Zhang, Ziwei, Wu, Yuan, Zhang, Wentao, Wang, Longsheng, Geng, Jiang, Yan, Yang, Yao, Xudong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333318/ https://www.ncbi.nlm.nih.gov/pubmed/30666091 http://dx.doi.org/10.2147/DDDT.S181122

Ejemplares similares

MicroRNA-154 functions as a tumor suppressor in bladder cancer by directly targeting ATG7
por: Zhang, Junfeng, et al.
Publicado: (2019)

Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer
por: Zhang, Wentao, et al.
Publicado: (2018)

Depletion of CDC5L inhibits bladder cancer tumorigenesis
por: Zhang, Ziwei, et al.
Publicado: (2020)

Depletion of CDC5L inhibits bladder cancer tumorigenesis: Erratum
por: Zhang, Ziwei, et al.
Publicado: (2022)

MicroRNA-153 Decreases Tryptophan Catabolism and Inhibits Angiogenesis in Bladder Cancer by Targeting Indoleamine 2,3-Dioxygenase 1
por: Zhang, Wentao, et al.
Publicado: (2019)

Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1
por: Zhang, Wentao, et al.
Publicado: (2023)

Preoperative C-reactive protein/albumin ratio is a significant predictor of survival in bladder cancer patients after radical cystectomy: a retrospective study
por: Guo, Yadong, et al.
Publicado: (2018)

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy
por: Guo, Yadong, et al.
Publicado: (2019)

Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer
por: Guo, Yadong, et al.
Publicado: (2019)

Suppressed OGT expression inhibits cell proliferation while inducing cell apoptosis in bladder cancer
por: Wang, Longsheng, et al.
Publicado: (2018)

Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis
por: Guo, Yadong, et al.
Publicado: (2019)

Association between perioperative glucocorticoids and cancer metastasis and survival in patients undergoing radical cystectomy for urothelial carcinoma of the bladder: A single-center retrospective study
por: Mao, Shiyu, et al.
Publicado: (2020)

Effects of radical cystectomy, radiotherapy, and chemotherapy on the risk of long-term heart-specific death in bladder cancer patients
por: Yang, Fuhan, et al.
Publicado: (2021)

Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report
por: Yang, Hong-Yu, et al.
Publicado: (2023)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
por: Gu, Yangchun, et al.
Publicado: (2021)

Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy
por: Guo, Yadong, et al.
Publicado: (2019)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Prognostic significance of red cell distribution width in bladder cancer
por: Ma, Wenchao, et al.
Publicado: (2020)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma
por: Wang, Longsheng, et al.
Publicado: (2019)

Overexpression of GAS6 Promotes Cell Proliferation and Invasion in Bladder Cancer by Activation of the PI3K/AKT Pathway
por: Mao, Shiyu, et al.
Publicado: (2020)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy
por: Zhang, Lu, et al.
Publicado: (2020)

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Gender dimorphism in survival of patients with lymph node metastasis of bladder cancer
por: Guo, Yadong, et al.
Publicado: (2022)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
por: Qu, Hong-Chen, et al.
Publicado: (2020)

Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
por: Fosså, S. D., et al.
Publicado: (1996)

Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
por: Wang, Bo, et al.
Publicado: (2018)

MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
por: Forschner, Andrea, et al.
Publicado: (2020)

Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis
por: Zhang, Jindong, et al.
Publicado: (2022)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Metastatic Pleural Effusion: An Unusual Presentation of Urothelial Bladder Carcinoma
por: Javed, Isma N, et al.
Publicado: (2019)

Small bowel obstruction secondary to metastatic urothelial bladder cancer
por: Wasfie, Tarik, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kra9eh5sdhv3t2ja3schm9uk47